Table 1 Patient characteristics by antipsychotic use at cohort entry for all patients and by diagnosis of a severe mental illness
From: Post-diagnostic antipsychotic use and cancer mortality: a population based cohort study
All breast cancer patients | Breast cancer patients with severe mental illness | |||
|---|---|---|---|---|
Antipsychotic user a | Antipsychotic non-user | Antipsychotic user a | Antipsychotic non-user | |
Total | 537 (2.3) | 23,158 (97.7) | 164 (49.1) | 170 (50.9) |
Year, n (%) | ||||
1998–2002 | 129 (24.0) | 5616 (24.3) | 36 (22.0) | 35 (20.6) |
2003–2007 | 203 (37.8) | 8592 (37.1) | 60 (36.6) | 59 (34.7) |
2008–2012 | 205 (38.2) | 8950 (38.6) | 68 (41.5) | 76 (44.7) |
Age, mean (SD) | 64.7 (14) | 62 (14) | 62.1 (11.5) | 65.4 (14.2) |
0–49 | 93 (17.3) | 4927 (21.3) | 20 (12.2) | 28 (16.5) |
50–59 | 118 (22.0) | 5799 (25.0) | 52 (31.7) | 35 (20.6) |
60–69 | 138 (25.7) | 5783 (25.0) | 51 (31.1) | 42 (24.7) |
70–79 | 188 (35.0) | 6649 (28.7) | 41 (25.0) | 65 (38.2) |
Deprivation, n (%) | ||||
1 (Least Deprived) | 98 (18.2) | 5927 (25.6) | 31 (18.9) | 33 (19.4) |
2 | 121 (22.5) | 5974 (25.8) | 28 (17.1) | 51 (30.0) |
3 | 116 (21.6) | 4767 (20.6) | 33 (20.1) | 34 (20.0) |
4 | 103 (19.2) | 3848 (16.6) | 32 (19.5) | 32 (18.8) |
5 (Most Deprived) | 99 (18.4) | 2633 (11.4) | 40 (24.4) | 20 (11.8) |
Breast cancer treatment, n (%) | ||||
Surgery | 350 (65.2) | 18,947 (81.8) | 116 (70.7) | 122 (71.8) |
Radiotherapy | 131 (24.4) | 8297 (35.8) | 45 (27.4) | 46 (27.1) |
Chemotherapy | 149 (27.7) | 6658 (28.8) | 37 (22.6) | 48 (28.2) |
Tamoxifen | 211 (39.3) | 9902 (42.8) | 59 (36.0) | 79 (46.5) |
Aromatase inhibitors | 152 (28.3) | 4854 (21.0) | 54 (32.9) | 45 (26.5) |
Grade, n (%) | ||||
1 | 67 (12.5) | 3717 (16.1) | 25 (15.2) | 28 (16.5) |
2 | 235 (43.8) | 10,057 (43.4) | 73 (44.5) | 72 (42.4) |
3 | 140 (26.1) | 6907 (29.8) | 41 (25.0) | 52 (30.6) |
4 | 2 (0.4) | 17 (0.1) | 0 | 0 |
Missing | 93 (17.3) | 2460 (10.6) | 25 (15.2) | 18 (10.6) |
Stage, n (%) | ||||
1 | 78 (14.5) | 4714 (20.4) | 31 (18.9) | 31 (18.2) |
2 | 89 (16.6) | 3844 (16.6) | 29 (17.7) | 33 (19.4) |
3 | 13 (2.4) | 733 (3.2) | * | * |
4 | 17 (3.2) | 291 (1.3) | * | * |
Missing | 340 (63.3) | 13,576 (58.6) | 95 (57.9) | 93 (54.7) |
Comorbidities, n (%) | ||||
Chronic pulmonary disease | 98 (18.2) | 3741 (16.2) | 25 (15.2) | 36 (21.2) |
Diabetes | 65 (12.1) | 1440 (6.2) | 16 (9.8) | 16 (9.4) |
Renal disease | 41 (7.6) | 1052 (4.5) | 28 (17.1) | 14 (8.2) |
Cerebrovascular disease | 24 (4.5) | 813 (3.5) | 9 (5.5) | 10 (5.9) |
Peptic ulcer disease | 16 (3.0) | 492 (2.1) | 4 (2.4) | 5 (2.9) |
Serious mental illness | 164 (30.5) | 170 (0.7) | 164 (100.0) | 170 (100.0) |
Statin use, n (%) | 92 (17.1) | 3454 (14.9) | 38 (23.2) | 29 (17.1) |
Aspirin use, n (%) | 97 (18.1) | 2901 (12.5) | 29 (17.7) | 31 (18.2) |
HRT use, n (%) | 151 (28.1) | 7571 (32.7) | 56 (34.1) | 62 (36.5) |
Smoking status, n (%) | ||||
Current | 264 (55.5) | 12,705 (61.3) | 71 (47.3) | 80 (53.0) |
Ex | 92 (19.3) | 4593 (22.2) | 28 (18.7) | 31 (20.5) |
Non-smoker | 120 (25.2) | 3431 (16.6) | 51 (34.0) | 40 (26.5) |
Missing | 61 | 2429 | 14 | 19 |
BMI, mean (SD) | 28.1 (6.1) | 27.0 (5.5) | 29.4 (5.9) | 27.1 (6.1) |